Table 3.

Delivery and Neonatal Outcomes in WLHIV on Elvitegravir During Pregnancy

	All (n = 140)	Singletons (n = 128)	Twins (n = 12)	P Value	No.
Delivery gestational age, y	38.2 (37.0–39.1)	38.3 (37.1–39.2)	36.8 (36.2–37.2)	.001	140
Preterm birth, <32 wk	5 (3.57)	5 (3.91)	0 (0.00)	1.000	140
Preterm birth, <37 wk	28 (20.0)	22 (17.2)	6 (50.0)	.015	140
Route of delivery				.021	139
C-section	66 (47.5)	56 (44.1)	10 (83.3)
Vaginal	73 (52.5)	71 (55.9)	2 (16.7)
Complications–hypertension	20 (14.3)	20 (15.6)	0 (0.00)	.215	140
Complications–postpartum hemorrhage	4 (2.86)	4 (3.12)	0 (0.00)	1.000	140
Complications–gestational diabetes	3 (2.14)	3 (2.34)	0 (0.00)	1.000	140
Complications–infection	3 (2.14)	3 (2.34)	0 (0.00)	1.000	140
Apgar score <7–1 min	23 (17.3)	20 (16.5)	3 (25.0)	.435	133
Apgar score <7–5 min	6 (4.51)	5 (4.13)	1 (8.33)	.439	133
Low birth weight	26 (19.1)	20 (16.1)	6 (50.0)	.012	136
NICU admission	20 (14.5)	18 (14.3)	2 (16.7)	.686	138
IUFD	2 (1.43)	2 (1.56)	0 (0.00)	1.000	140
Birth defect	2 (1.46)	2 (1.60)	0 (0.00)	1.000	137
Neonatal HIV status				1.000	132
Negative	131 (99.2)	121 (99.2)	10 (100)
Positive	1 (0.76)	1 (0.82)	0 (0.00)
Neonatal prophylaxis				1.000	110
Zidovudine	100 (90.9)	90 (90.0)	10 (100)
Zidovudine/nevirapine	6 (5.45)	6 (6.00)	0 (0.00)
Zidovudine/nevirapine/lamivudine	4 (3.64)	4 (4.00)	0 (0.00)

Data are presented as No. (%) or median (interquartile range).

Abbreviations: IUFD, intrauterine fetal demise; NICU, neonatal intensive care unit; WLHIV, women living with HIV.